Thor Medical Asa · OSL:TRMED
Thor Medical Asa — Shareholder Meeting (April 2024)
13 slides from Thor Medical Asa's shareholder meeting presentation, Apr 11, 2024
Slide 1: CEO presentation AGM 2024
CEO presentation AGM 2024 Update on current development activities in Thor Medical 11 April 2024
Slide 2: Becoming a world-leading supplier of alpha-emitters for cancer therapy
Becoming a world-leading supplier of alpha-emitters for cancer therapy Cancer is a leading cause of death worldwide, accounting for around 10 million deaths per year Radiotherapeutics represents one of the fastest growing cancer treatment options Thor Medical enables a transformation of cancer care
Slide 3: Radiotherapeutics represent a large market opportunity
Radiotherapeutics represent a large market opportunity Global radiopharmaceutical market USDbn • New cancer radiotherapeutics have reached sales in the USD hundreds of millions • Several hundred radiopharmaceuticals in development, creating strong future demand 27 for radioactive compounds • Next-ge
Slide 4: Proprietary and verified technology offering the world's purest radionuclides
Proprietary and verified technology offering the world’s purest radionuclides Thor Medical manufacturing process • Natural thorium Th-232 as feedstock for Th-232 Natural thorium as Thor Medical’s process feedstock • Delivering high purity Th-228, Proprietary independent of nuclear reactors or separa
Slide 5: Turning waste into next-generation cancer therapies
Turning waste into next-generation cancer therapies Proprietary process Generating Ra- Distribution to Thorium-232 for separation of 224/Pb-212 and hospitals and cancer – a naturally Th-232 into the linking to targeting clinics for patient occurring isotope world’s purest molecule to create treatmen
Slide 6: Sourcing of feedstock of natural Thorium-232
Sourcing of feedstock of natural Thorium-232 • Th-232 is a biproduct from many mining activities which opens several opportunities for Thor Medical medium/long term • Currently qualifying one supplier with concentrated Th-232 commercially available • Negotiations with several other potential supplie
Slide 7: Proprietary separation process and purification of alpha-emitters
Proprietary separation process and purification of alpha-emitters Thor Medical’s proprietary separation process / IP Pre-processing naturally occurring thorium Proven and scalable 1 Spec and pre-processing of Th-232 for producing Th-232 separation method alpha-emitters with 99.9% yield Large-scale s
Slide 8: Building pilot facilities at Herøya to prepare for industrialization
Building pilot facilities at Herøya to prepare for industrialization • Investing NOK ~10m in pilot facilities at Herøya with NOK 6m grant from Innovation Norway Pilot completion in 2H 2024 provides basis for: • Verification of production process and technology • Producing customer samples from 2H 20
Slide 9: Customer relations
Customer relations Indicated demand is 4-5x the planned industrial scale plant capacity Companies focusing on Pb-212 and Ra-224 >300 GBq • We have signed three LoI with potential customers Additional • Customers progressing in clinical indicated trials, indicating we might get orders demand earlier
Slide 10: Roadmap to FID on industrial scale production
Roadmap to FID on industrial scale production 2024- 2025 FID 2025 - 2027 2027- 2030 Establish Pilot plant at Herøya for product and process verification • Verify process and production technology • Produce customer samples • Case-study for scale-up to industrial-scale manufacturing Construction Prod
Slide 11: Opportunity to fast-track industrial-scale volumes to market by 2025
Opportunity to Thor Medical progressing well in all aspects of the value chain to become a leading supplier of alpha-emitters with fast-track pilot plant start-up scheduled for second half of 2024 industrial-scale Customers progressing with clinical trials and requesting volumes to market high purit
Slide 12: Conclusions
Conclusions 1 Thor Medical has a small, but complete organization to cover all challenges on the way to become a high-quality supplier in the global radiopharmaceutical market 2 We are making progress on all aspects of the value chain with planned pilot plant start-up in 2H 2024 for delivering produ
Slide 13: thormedical.no
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, for medical use in cancer therapy. Its proprietary production technology requires no irradiation, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceut